Dexcom Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 6,339,900,000.00 | ROE | 43.31 % |
| Balance Sheet | Total Equity | 2,746,000,000.00 | ROA | 13.19 % |
| Cashflow | Capital Expenditures | -363,500,000.00 | P/FCF | 31.42 |
| Cashflow | Free Cash Flow | 1,077,200,000.00 | – | – |
| Cashflow | Operating Cash Flow | 1,440,700,000.00 | P/CF | 23.49 |
| Income | Earnings per Share (diluted) | 2.06 | Div. Yield | – |
| Income | Net Income | 836,300,000.00 | P/E | 40.52 |
| Income | Shares Outstanding | 391,800,000.00 | P/B | 12.33 |
| Income | Total Revenue | 4,662,000,000.00 | P/S | 7.26 |
Ratios calculated on: 10/14/2026
Company Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.dexcom.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more